Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15586456 | 0.73 | HTR2A (0.42) | SLC6A2SLC6A4SLC6A3HTR2ACA1 | |
| SCHEMBL5995198 | 0.71 | POLL (0.47) | ACHEHTR2ACA1CA2CYP19A1 | |
| SCHEMBL4403294 | 0.69 | CYP19A1 (0.44) | ACHEDRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL25604495 | 0.68 | ACHE (0.44) | ACHEDRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL5995147 | 0.68 | CHRNB2 (0.44) | — | |
| SCHEMBL15773405 | 0.67 | HSD11B1 (0.48) | ACHEDRD2DRD3CHRM2CHRM1 | |
| SCHEMBL3148251 | 0.67 | HTR2A (0.54) | ACHEDRD2DRD3HTR2ACHRM2 | |
| SCHEMBL5997652 | 0.67 | HSD11B1 (0.42) | ACHEDRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL6153138 | 0.66 | HTR2C (0.46) | DRD2HTR2ACA1CA2CYP19A1 | |
| SCHEMBL15773366 | 0.66 | ACHE (0.49) | ACHEDRD2DRD3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122534-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-10-17 | — | — | US | disclosed |
| US-20040167149-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2004-08-26 | — | — | US | disclosed |
| US-6706702-B2 | FOR THERAPY OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | PFIZER INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1076650-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030130261-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2003-07-10 | — | — | US | disclosed |
| US-20030008890-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2003-01-09 | — | — | US | disclosed |
| US-6462035-B1 | BINDING TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR; MODULATING CHOLINERGIC FUNCTION; REDUCING NICOTINE ADDICTION; INFLAMMATORY AND IRRITABLE BOWEL SYNDROME, SPASTIC DYSTONIA, CHRONIC AND ACUTE PAIN, EATING DISORDERS | PFIZER INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1076650-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999055680-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130261-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN3A | ACHE 237/4885DRD2 75/4885DRD3 82/4885 |
| US-20030008890-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, NR3C1 | ACHE 176/4885DRD2 75/4885DRD3 78/4885 |
| US-20040167149-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, NR3C1 | ACHE 176/4885DRD2 75/4885DRD3 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.